VRTX Earnings Date: Nov 2, 2026 (Estimated) — Vertex Pharmaceuticals Incorporated
NASDAQ · Healthcare · Biotechnology
Updated
When is VRTX's next earnings date?
Vertex Pharmaceuticals Incorporated (VRTX) is expected to report Q3 2026 earnings on Monday, November 2, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $4.80 on revenue of $3.42B.
How did VRTX do in its last earnings report?
In its most recent report on Aug 3, 2026 (Q2 2026), Vertex Pharmaceuticals Incorporated posted EPS of $4.73 versus the $4.63 estimate, a beat of 2.2%. Revenue was $3.33B against a $3.21B estimate. The stock's 1-day post-earnings move was +1.7%.
How much does VRTX stock move after earnings?
VRTX beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 6.1% (up or down) in the day after earnings.
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-03 | Q2 2026 | 4.63 | 4.73 | +2.16% | $3.33B | ✅ Beat | +1.70% | +11.30% | +16.34% |
| 2026-05-04 | Q1 2026 | 4.18 | 4.47 | +6.94% | $2.99B | ✅ Beat | -1.28% | +1.24% | -0.35% |
| 2026-02-12 | Q4 2025 | 4.85 | 5.03 | +3.71% | $3.19B | ✅ Beat | +5.69% | +2.55% | +0.23% |
| 2025-11-03 | Q3 2025 | 4.35 | 4.80 | +10.34% | $3.08B | ✅ Beat | -1.02% | -1.13% | +8.72% |
| 2025-08-04 | Q2 2025 | 4.05 | 4.52 | +11.88% | $2.96B | ✅ Beat | -20.60% | -20.71% | -16.02% |
| 2025-05-05 | Q1 2025 | 4.29 | 4.06 | -5.36% | $2.77B | ❌ Miss | -10.03% | -12.16% | -10.86% |
| 2025-02-10 | Q4 2024 | 4.02 | 3.98 | -1.00% | $2.91B | ❌ Miss | -3.14% | -1.67% | +5.42% |
| 2024-11-04 | Q3 2024 | 4.14 | 4.38 | +5.80% | $2.77B | ✅ Beat | +5.73% | +6.12% | -1.87% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $3.21B total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| TRIKAFTA/KAFTRIO | 77.8% | $2.50B | -2.1% | $2.72B | $2.54B | $2.55B | $2.65B |
| ALYFTREK | 17.9% | $573.6M | +265.8% | — | $53.9M | $156.8M | $247.0M |
| Manufactured Product, Other | 4.3% | $137.1M | -41.9% | $594.6M | $170.8M | $236.1M | $175.8M |
By region
Q2 FY26 · $4.61B total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 44.6% | $2.06B | +12.5% | $1.84B | $1.65B | $1.83B | $1.98B |
| Non-US | 34.2% | $1.58B | — | — | — | — | $1.36B |
| Europe | 21.2% | $977.7M | +7.3% | $832.0M | $826.6M | $910.9M | $836.9M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.